Arvind Dasari, MD
Hematology & Oncology · Houston, TXNPI 1497927123
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $57,323 of the $76,814 with a category attached, or 74.6%. 19 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.4% of the total. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $1097.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$26K
- Sirtex Medical Inc$7K
- Exelixis Inc.$7K
- Taiho Oncology, Inc.$6K
- Novartis$6K
- Advanced Accelerator Applications$5K
- plus $22K from 13 others
Across 15 payments — averaging $132,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$859K
- E.r. Squibb & Sons, L.L.C.$704K
- Eisai Inc.$412K
- Taiho Oncology, Inc.$12K
What the payments were for
- Consulting fees$57,32375%
- Speaking & faculty fees$12,11816%
- Travel & lodging$4,9186%
- Food & beverage$2,2053%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $25,684 |
| Sirtex Medical Inc | 4 | $6,678 |
| Exelixis Inc. | 13 | $6,631 |
| Taiho Oncology, Inc. | 4 | $5,742 |
| Novartis | 3 | $5,579 |
| Advanced Accelerator Applications | 2 | $4,844 |
| Bayer | 6 | $4,476 |
| Sanofi | 2 | $3,855 |
| Lexicon Pharmaceuticals, Inc. | 1 | $3,780 |
| Lantheus Medical Imaging, Inc. | 1 | $2,835 |
| Ipsen Biopharmaceuticals, Inc | 3 | $2,206 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,910 |
| Roche Molecular Systems, Inc. | 2 | $1,400 |
| Shionogi Inc | 3 | $816 |
| Tersera Therapeutics LLC | 1 | $112 |
| Eisai Inc. | 2 | $100 |
| Pfizer | 1 | $97 |
| Pulmonx Corporation | 1 | $41 |
| Incyte Corporation | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$23,494
- SIR-Spheres Microspheres$6,644
- Cabometyx$6,343
- Lonsurf$5,742
- Lutathera$4,844
- Xermelo$3,892
- Stivarga$2,272
- SOMATULINE DEPOT$2,100
- Nexavar$2,097
How this compares
$76,814 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 42 | $249,883 |
| Prochlorperazine Maleate | 26 | $393 |
| LoperamideLoperamide Hcl | 13 | $275 |
| Ondansetron Hcl | 30 | $167 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.